A n individual's reaction to infection is triggered by bacterial toxins or by components of microbial cells, such as cell membrane fragments (1) . Although this is ostensibly a defensive reaction designed to overcome the infection and to eliminate bacterial breakdown products, the elements of the patient's response may themselves elicit toxic reactions, resulting in the potentially fatal sepsis syndrome. In the United States, Ͼ500,000 patients develop sepsis each year and ϳ50% of these patients die (2) .
The normal reaction to infection involves a series of complex immunologic processes. For example, factors associated with Gram-positive and Gram-negative bacterial infections trigger the macrophages to produce cytokines, including tumor necrosis factor (TNF) and interleukin (IL)-1 (3). These proinflammatory peptides, in turn, elicit a number of reactions, including adhesion of leukocytes to endothelial cells (4, 5) .
As a result, it has been proposed that blocking proinflammatory cytokines may improve survival after lethal challenge. Indeed, experimental studies showed that administration of anti-TNF monoclonal antibodies to animals challenged with intravenous Escherichia coli significantly decreased the mortality rate. When the blocking antibody was given 2 hrs before the E. coli challenge, all of the animals survived, whereas all of the animals died if they remained untreated (6) .
However, there are two caveats that preclude generalization from these and other cytokine-blocking experiments. First, blocking the actions of proinflammatory cytokines is only successful if given before the challenge (7) . Second, the cytokine blockade is only effective if the toxic challenge is hyperacute, as in the intravenous administration of a bolus containing billions of E. coli or of a large amount of endotoxin. Indeed, if the challenge is subacute, as in the experimental models involving peritonitis or cecal ligation and puncture, cytokine blockade has been mostly unsuccessful (7) .
The recent challenges to these two caveats have been based on the identification, and blocking, of two newly identified mediators. Tracey and colleagues defined high motility group protein 1, a cytokine that is released on stimulation of macrophages by endotoxin (8) . Its levels peak more slowly (ϳ15 hrs) than do those of TNF or IL-1, which are released from macrophages and peak 1-2 hrs after lipopolysaccharide (LPS) challenge. The administration of antibody to high motility group protein 1 successfully attenuated endotoxin-induced mortality in mice, even when administration of the blocking antibody was delayed by as long as 24 hrs after challenge (9) .
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Conclusions
In addition to inducing the release of mediators, which may themselves induce tissue injury, endotoxin produced by bacteria or other cell wall components of the microbial organisms may elicit tissue damage directly by activating pathways such as the coagulation cascade (13, 14) , the complement cascade (15, 16), vessel injury, or the release of arachidonic acid metabolites or nitric oxide (1) . Thus, the processes that result in the sepsis syndrome, with circulatory collapse, organ failure, and death, are the complex consequences of microbial products that profoundly dysregulate mediator release and the homeostasis of several important pathways (17) .
Current Therapeutic Rationales. As a result of increasing knowledge of the processes involved in inflammation, it has been proposed that it is possible to treat sepsis by blocking individual mediators or some of the common pathways (Table  1) (3, 18 -20) . Unfortunately, clinical use of such blocking agents has failed to reduce the overall mortality associated with sepsis. Thus, Ͼ30 randomized blinded studies involving Ͼ12,000 patients have shown that the use of blocking antibodies does not beneficially influence either the clinical course or the mortality of patients with sepsis and may sometimes actually be harmful (3, 18 -21) .
These disappointing results do not negate the validity of the concept of therapeutically blocking cytokines or modulating the inflammatory response to infection. Indeed, successful outcomes have been achieved when the inflammatory reaction is triggered by a welldefined process. For example, successful modification of the Jarisch-Herxheimer reaction has been achieved by blocking TNF (22) . Similarly, successful modification of rheumatoid arthritis (23) and Crohn's disease (24, 25) has been described in patients treated with TNFblocking agents. Thus, interference with the actions of individual cytokines is effective in modifying the course of some well-characterized inflammatory reactions. However, in complex situations such as sepsis or septic shock, multiple cellular activation processes are involved and many humoral cascades are triggered, so that merely blocking a single component may be insufficient to arrest the inflammatory process. For example, microbial cell wall components stimulate inflammation and toxic reactions indirectly via the mediation of cytokines as well as by directly stimulating cascades such as coagulation or complement. Although blocking cytokine action can modulate the former processes, such blockade does not interrupt cascades that have been activated directly. It has therefore been suggested that the direct blocking of microbial products before they stimulate responsive cells or inflammatory cascades may provide a more successful therapeutic approach for the management of the sepsis syndrome and septic shock.
Potential Future Strategies in the Treatment of Septic Shock. Some of the molecular and cellular processes involved in triggering an inflammatory reaction have been well defined. For Gramnegative bacteria, endotoxin (LPS) triggers the sepsis syndrome. LPS binds to a specific protein (LPS-binding protein [LBP] ) in the plasma. LBP, in turn, most likely acts to catalyze the transfer of LPS monomers from LPS aggregates (1, 26) . LBP greatly increases sensitivity to minute amounts of LPS, so that effector cells are triggered and bacteria can be cleared. The complex of LPS and LBP binds to a macrophage membrane receptor, CD14. This receptor presents LPS to a signal transducing receptor in the membrane (Toll-like receptor, TLR) resulting in macrophage activation ( Fig. 1 ) (17) .
Gram-positive organisms can trigger sepsis and septic shock by at least two mechanisms (26) . First, bacteria such as staphylococci or streptococci produce exotoxins that act as "superantigens" (27, 28) . Second, Gram-positive bacteria release cell membrane fragments that can activate the sequence of processes culminating in septic shock (26) .
The superantigens are not a common cause of sepsis. The staphylococcal superantigen (toxic shock syndrome toxin-1) and the streptococcal superantigen (streptococcal pyrogenic exotoxin) are the two most well known. Unlike antigens, bacterial superantigens can induce T cell proliferation without regard to the antigenic specificity of the T cell. Superantigens interact directly with MHC class II receptors on macrophages and with the V-beta chain of T cell receptors, resulting in the activation of both macrophages and T cells. Up to 20% of all T cells are potentially stimulated in this way (29) , with a consequent enormous release of cytokines. The result is staphylococcal or streptococcal toxic shock syndrome, with fever, hypotension, and organ failure (28) .
More often, Gram-positive organisms elicit sepsis and septic shock in the absence of exotoxins, as a result of the action of the whole organism or of cell wall components, including peptidoglycans, teichoic acids, and lipoteichoic acids. These cell wall components can trigger the release of cytokines, the generation of complement, aggregation of platelets, ac- PAF, platelet-activating factor; PG, prostaglandin; IL-1-ra, interleukin-1-receptor antagonist; TNF, tumor necrosis factor; mAb, monoclonal antibody; SR, soluble receptor; NO, nitric oxide. tivation of coagulation, and an increase in cell membrane permeability. Whole bacterial cells and lipoteichoic acid induce release of TNF much less effectively than does LPS. To induce TNF release in quantities similar to those released by LPS, ϳ1,000 times as much peptidoglycan is required, whereas lipoteichoic acid is 100 times less potent than LPS (30) . Gram-positive cell wall fragments are believed to be presented to the CD14 receptor by a still unknown serum protein that, in turn, presents to the hTLR2 receptor ( Fig. 1) (17, 26, 31 ). Moreillon and colleagues sought a component of Grampositive bacterial cell walls that would be as potent as LPS in triggering cytokine release using the naturally occurring enzymes amidase and glucosidase to digest and solubilize pneumococcal cell walls. The principal components isolated via chromatography were then tested for TNF-releasing activity. Small amounts of material, composed of tripeptides or more complex peptides, were obtained with high cytokine-releasing activity similar to LPS. Thus, peptidoglycan stem peptides, derived from components of Gram-positive bacterial cell walls, might represent one of the triggers responsible for septic shock syndrome.
Inflammatory Response and Innate Immunity. Functionally, innate immunity with its germ-line encoded receptors for the recognition of microbial pathogens, represents a phylogenetically ancient defense against microorganisms (33) (34) (35) . Acquired immunity relies on the memory of previously encountered pathogens and results from the generation of a large repertoire of antigenrecognizing receptors. The tight relationship between innate immunity, as studied in insects, and the inflammatory response in vertebrates has only recently been defined.
Embryologists studying the development of larval stages of Drosophila described a pathway controlling the dorsoventral polarization of the embryo. The pathway was activated by the Toll receptor, whose intracellular signaling pathway is similar to the IL-1 receptor pathway in mammals (36) . The IL-1 receptor cytoplasmic domain in mammalian cells induces proteins of the NF-B family of transactivators (1, 36) , which, in turn, control expression of the genes for cytokines, such as IL-1, IL-6, and IL-8, as well as for chemokines (37) . The similarities between embryonic developmental pathways in Drosophila and the acute phase response pathways in mammals (16) led to the discovery that, in adult flies, the Toll receptor pathway regulates production of one of the major defensins, drosomycin, which is particularly active against fungal infections in flies (38) . The defensins in insects, plants, and mammals are an integral part of innate immunity. This led rapidly to the discovery of a human homolog to the Toll receptor (36), the ligand for which is endotoxin.
Microbes display a limited number of pathogen-associated molecular patterns that are recognized by soluble or cellbound pattern recognition receptors (16, 34, 35) . The microbial molecular patterns represent structures essential for survival of the microbes and are not found in mammals. They include LPS of Gramnegative bacteria, peptidoglycans and lipoteichoic acids of Gram-positive bacteria, glycolipids of mycobacteria, mannans of yeasts, and double-stranded RNA of viruses. These highly conserved structures elicit defensive reactions by stimulating either pattern recognition soluble molecules or receptors on cells such as macrophages and endothelial cells. Examples of pattern recognition molecules and pattern recognition receptors include hTLR4 for LPS, hTLR2 for lipoteichoic acid, peptidoglycan of Gram-positive bacteria, and lipoarabinomannan of mycobacteria ( Table 2 ). The significance of the recognition molecules is emphasized by the consideration that because the general structure of LPS is common to all Gram-negative bacteria, for example, a receptor that recognizes the lipid A component of LPS can detect the presence of any Gram-negative bacteria (33) .
Although activation pathways of innate immunity in adult insects and plants appear to regulate the production of antimicrobial peptides, the mechanisms of innate immunity in mammals play a key role in stimulating and orientating primary adaptive immune responses (33, 35) by controlling the expression of costimulatory molecules, such as cytokines and chemokines (16, 34) . The function of innate immunity, in relation to adaptive immunity, is therefore thought to involve signaling the presence of microbes and their need to mount an immune response. In the absence of such a signal, however, the adaptive immune response is driven toward inactivity or tolerance (33) .
Sepsis and Septic Shock: A Dysregulation of Innate Immunity. It now appears clear that the manifestations of sepsis and septic shock result from dysregulation of innate immunity. These processes are highly conserved with respect to the triggering mechanism and in the subsequent responses. Because the triggers of innate immunity involve a limited number of molecular structures that are recognized by a limited number of pattern recognition receptors, a better understanding of these processes may help to devise strategies to prevent dysregulation. For example, blocking microbial molecular structures may be beneficial because the number of stimulating molecules is limited and the activation processes involve only a few pathways. Moreover, because the coagulation and complement cascades are likely also activated by these microbial molecular patterns, blocking microbial products may prevent a large array of the toxic manifestations of sepsis. Other protective measures may involve interference with or prevention of the stimulation of responsive cells by blocking the intracellular mechanisms activated by the reaction to microbial products.
CONCLUSIONS
The development of the sepsis syndrome and septic shock reflect excessive stimulation of the processes of innate immunity. In addition to stimulating the production of cytokines and chemokines, activation of the coagulation and complement cascades are also invoked. These processes are triggered by a limited number of conserved microbial molecular patterns, each characteristic of large groups of microbial pathogens. The microbial components, in turn, are recognized by a limited number of pattern-recognition molecules, either soluble or cell-bound. In the course of infection, the bacterial components reacting with specific receptors (eg, CD14 and TLR in the case of LPS) activate the intracellular processes, resulting in the release of excessive amounts of mediators of inflammation, as well as triggering multiple complex proteolytic cascades (such as coagulation).
In keeping with the complexity of the reactions involved in sepsis, blockade or antagonism of the actions of individual intermediary messenger molecules (eg, cytokines) has proved therapeutically unsuccessful. This is most likely attributable to the fact that mere blockade of mediators alone does not block the direct activation of the various pathways such as coagulation, complement, and nitric oxide release. However, it seems possible that the dysregulation that characterizes sepsis may be amenable to blockade of the noxious bacterial components or to the intracellular pathways triggered by these products, thus providing a promising future for the therapy of sepsis and septic shock. 
